Meeting
2012 ASCO Annual Meeting
A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.
Authors
Eric Jeffrey Sherman
Memorial Sloan-Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , Alan Loh Ho , Matthew G. Fury , Shrujal S. Baxi , Sofia Haque , Susan H. Korte , Stephanie Smith-Marrone , Han Xiao , Ronald A. Ghossein , James A. Fagin , David G. Pfister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01025453
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5514)
DOI
10.1200/jco.2012.30.15_suppl.5514
Abstract #
5514
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.
First Author: Eric Jeffrey Sherman
Poster
2014 ASCO Annual Meeting
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
First Author: Mairead Geraldine McNamara
Poster
2013 ASCO Annual Meeting
Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
First Author: Leena Gandhi
Poster
2022 ASCO Annual Meeting
Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).
First Author: Bharat Burman